Skip to content
Monday 10 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,870.86
-0.28%
DAX
26,411.55
+0.35%
CAC 40
8,721.28
+0.07%
STOXX 50
6,552.01
+0.43%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

GSK

  • GlaxoSmithKline considers £17bn HIV wonder drugs split with Viiv Healthcare IPO

    October 22, 2014

    Pharma giant GlaxoSmithKline (GSK) is considering floating its HIV drugs business in a move that would see Viiv Healthcare among the top 40 companies in the FTSE 100 with a market valuation of up to £17bn. Chief executive Andrew Witty told reporters yesterday: “In line with our commitment to identifying ways to realise shareholder value, [...]

  • FTSE rises after Glaxo sets out recovery plan – London Report

    October 22, 2014

    BRITAIN’S top share index yesterday ended higher, with motor insurers advancing on news of an increase in car premiums and drugmaker Glaxo­Smith­Kline rising after its results. The FTSE 100 finished 0.4 per cent higher at 6,399.73 points. It had fallen more than 10 per cent in four weeks before making a marginal recovery since late [...]

  • GSK healthcare spin-off ViiV could generate one of the biggest IPOs in history: Here are some of the most successful corporate spin-offs stories

    October 22, 2014

    ViiV Healthcare could generate one of the biggest IPOs in history, if GSK decides to go ahead and make it a spin-off company.   The pharmaceutical firm was created in 2009 as a joint venture between GSK and US firm Pfizer. It specialises in developing therapies for HIV and operates in 16 countries.   With [...]

  • GSK share price up despite Ebola vaccine delay: Head of research says it will be “too late” for this epidemic

    October 17, 2014

    GlaxoSmithKline (GSK) has revealed that its Ebola vaccine won't be ready in time to deal with the current epidemic in west Africa.    The British pharmaceutical giant started developing the vaccine earlier this year, in conjunction with the US National Institutes of Health. It uses a single protein from the Ebola virus to set off [...]

  • GSK confirms RBS’ Sir Philip Hampton as new chairman

    September 25, 2014

    GlaxoSmithKline (GSK) has confirmed that Royal Bank of Scotland (RBS) chairman Sir Philip Hampton has been appointed to lead its board. The pharmaceutical giant said this morning that Hampton will join as non-executive director on 1 January next year, assuming the role of chairman from Sir Christopher Gent from 1 September. Although RBS did not [...]

  • GlaxoSmithKline to name Sir Philip Hampton chair

    September 24, 2014

    SHARES in pharmaceutical giant Glaxo­SmithKline (GSK) rose slightly in late afternoon trading yesterday after it emerged that Sir Philip Hampton was likely to be named as its new chairman. GSK is likely to announce Hamp­ton’s move in the next two days – and with such a large job he is expected to eventually give up [...]

  • Share price up after rumours RBS’ Sir Philip Hampton “will be named GSK chairman before the weekend”

    September 24, 2014

    Shares in pharmaceutical giant GlaxoSmithKline rose slightly in late afternoon trading after it emerged Sir Philip Hampton is likely to be named as its new chairman. Shares climbed 0.2 per cent to 1,425p, having spent the afternoon around the 1,418p mark. GSK is likely to announce Hampton's move in the next two days – such [...]

  • GSK share price shows immunity to Ebola vaccine

    September 17, 2014

    The news GSK’s Ebola vaccine is to be trialled on humans failed to lift the company on the stock market this morning, with its share price falling 0.21 per cent to 1,438 pence.   The experimental vaccine is to be tested on 60 healthy adults in Oxford, after it conferred resistance on a group of [...]

  • GSK share price falls, despite Ebola vaccine success

    September 8, 2014

    Monkeys given an experimental Ebola vaccine developed by GSK were resistant to the deadly virus when infected with it five weeks later, trials have shown.   The results of a drug trial, published in the journal Nature, show all of the monkeys not given the vaccine died within 6 days of infection, whereas the four [...]

  • GSK Ebola vaccine to be tested in UK

    August 28, 2014

    An international consortium is fast-tracking an Ebola vaccine under development by the US National Institutes of Health (NIH) and GlaxoSmithKline, with human trials set to begin in the UK as early as September.   The move follows a declaration by the World Health Organisation (WHO) that the Ebola outbreak in West Africa is a public [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • …
  • Page 22
  • Next

Trending Articles

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • Hargreaves Lansdown orders staff back to office

  • FTSE 100 Live: Stocks drop as US-Iran peace stalls; Oil climbs higher

  • PwC’s Embankment HQ to get major makeover ahead of Canary Wharf move

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook